Firefly Health vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 34)
Firefly Health logo

Firefly Health

EmergingHealthTech

Virtual Primary Care

Firefly Health operates a virtual-first primary care practice with dedicated care teams, offering comprehensive primary care, mental health, and chronic disease management through a mobile app.

AI VisibilityBeta
Overall Score
D34
Category Rank
#580 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
29
Perplexity
38
Gemini
36

About

Firefly Health delivers virtual-first primary care through a model built around dedicated care teams — a physician, health coach, and care coordinator assigned to each patient — rather than the on-demand provider matching used by most telehealth platforms. Patients access their care team through the Firefly app for video visits, messaging, lab result review, specialist referrals, and care plan management, with the team maintaining longitudinal knowledge of their health history and goals.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

34
Overall Score
80
#580
Category Rank
#18
77
AI Consensus
83
stable
Trend
stable
29
ChatGPT
78
38
Perplexity
78
36
Gemini
80
31
Claude
84
31
Grok
77

Key Details

Category
Virtual Primary Care
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Firefly Health
Virtual Primary Care

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.